CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia.
Alzheimer Disease
/ metabolism
Amyloid beta-Protein Precursor
/ genetics
Animals
Brain
/ metabolism
Disease Models, Animal
Humans
Mice
Microglia
/ metabolism
Nerve Degeneration
/ pathology
Neurofibrillary Tangles
/ pathology
Plaque, Amyloid
/ pathology
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
/ antagonists & inhibitors
tau Proteins
/ genetics
ATN-continuum
Alzheimer’s disease
Amyloid pathology
CSF1R inhibition
Microglial profiling
Microgliosis
Neurodegeneration
Tau pathology
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
18
05
2021
accepted:
19
05
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Alzheimer's disease (AD) is characterized by a sequential progression of amyloid plaques (A), neurofibrillary tangles (T) and neurodegeneration (N), constituting ATN pathology. While microglia are considered key contributors to AD pathogenesis, their contribution in the combined presence of ATN pathologies remains incompletely understood. As sensors of the brain microenvironment, microglial phenotypes and contributions are importantly defined by the pathologies in the brain, indicating the need for their analysis in preclinical models that recapitulate combined ATN pathologies, besides their role in A and T models only. Here, we report a new tau-seed model in which amyloid pathology facilitates bilateral tau propagation associated with brain atrophy, thereby recapitulating robust ATN pathology. Single-cell RNA sequencing revealed that ATN pathology exacerbated microglial activation towards disease-associated microglia states, with a significant upregulation of Apoe as compared to amyloid-only models (A). Importantly, Colony-Stimulating Factor 1 Receptor inhibition preferentially eliminated non-plaque-associated versus plaque associated microglia. The preferential depletion of non-plaque-associated microglia significantly attenuated tau pathology and neuronal atrophy, indicating their detrimental role during ATN progression. Together, our data reveal the intricacies of microglial activation and their contributions to pathology in a model that recapitulates the combined ATN pathologies of AD. Our data may provide a basis for microglia-targeting therapies selectively targeting detrimental microglial populations, while conserving protective populations.
Identifiants
pubmed: 34103079
doi: 10.1186/s40478-021-01204-8
pii: 10.1186/s40478-021-01204-8
pmc: PMC8188790
doi:
Substances chimiques
Amyloid beta-Protein Precursor
0
Csf1r protein, mouse
0
MAPT protein, human
0
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Références
Cell Rep. 2020 Sep 29;32(13):108189
pubmed: 32997994
Immunity. 2017 Sep 19;47(3):566-581.e9
pubmed: 28930663
Nat Commun. 2016 Jul 04;7:12082
pubmed: 27373369
Acta Neuropathol. 2019 Mar;137(3):397-412
pubmed: 30599077
J Neurosci. 2006 Oct 4;26(40):10129-40
pubmed: 17021169
J Neuroinflammation. 2020 May 6;17(1):151
pubmed: 32375809
Acta Neuropathol. 2019 Dec;138(6):913-941
pubmed: 31414210
Protein Sci. 2018 Nov;27(11):1901-1909
pubmed: 30125425
Acta Neuropathol. 2015 Jun;129(6):875-94
pubmed: 25862635
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
EMBO Mol Med. 2020 Mar 6;12(3):e10606
pubmed: 31951107
Am J Pathol. 2017 Jul;187(7):1601-1612
pubmed: 28500862
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Neurobiol Aging. 2016 Jan;37:19-25
pubmed: 26481403
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurobiol Dis. 2020 Aug;142:104956
pubmed: 32479996
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Nat Med. 2020 Jan;26(1):131-142
pubmed: 31932797
Nature. 2019 Nov;575(7784):669-673
pubmed: 31748742
Brain. 2020 Mar 1;143(3):1010-1026
pubmed: 32179883
Cell. 2015 Mar 12;160(6):1061-71
pubmed: 25728668
Nat Neurosci. 2015 Nov;18(11):1584-93
pubmed: 26436904
Nature. 2017 Sep 28;549(7673):523-527
pubmed: 28959956
Mol Neurodegener. 2014 Nov 18;9:51
pubmed: 25407337
Acta Neuropathol. 2019 Apr;137(4):599-617
pubmed: 30721409
FASEB J. 2014 Jun;28(6):2620-31
pubmed: 24604080
JAMA Neurol. 2019 Aug 1;76(8):915-924
pubmed: 31157827
Nature. 2019 Jun;570(7761):332-337
pubmed: 31042697
J Exp Med. 2016 May 2;213(5):667-75
pubmed: 27091843
Nat Rev Immunol. 2018 Dec;18(12):759-772
pubmed: 30140051
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Nat Neurosci. 2019 Dec;22(12):2087-2097
pubmed: 31768052
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Neuron. 2017 Oct 11;96(2):313-329.e6
pubmed: 29024657
Neuron. 2016 May 18;90(4):724-39
pubmed: 27196974
Science. 2001 Aug 24;293(5534):1487-91
pubmed: 11520987
Science. 2001 Aug 24;293(5534):1491-5
pubmed: 11520988
Nature. 2006 Mar 16;440(7082):352-7
pubmed: 16541076
Nat Commun. 2019 Aug 21;10(1):3758
pubmed: 31434879
J Clin Invest. 2020 Sep 1;130(9):4954-4968
pubmed: 32544086
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Nat Med. 2019 Nov;25(11):1680-1683
pubmed: 31686034
J Exp Med. 2019 Nov 4;216(11):2546-2561
pubmed: 31601677
Nat Neurosci. 2020 Mar;23(3):311-322
pubmed: 32112059
Neurobiol Dis. 2015 Jan;73:83-95
pubmed: 25220759
Nat Med. 2018 Jan;24(1):29-38
pubmed: 29200205
Brain. 2019 Oct 1;142(10):3243-3264
pubmed: 31504240
Brain. 2016 Apr;139(Pt 4):1265-81
pubmed: 26921617
Am J Pathol. 2007 Dec;171(6):2012-20
pubmed: 18055549
F1000Res. 2016 Aug 31;5:2122
pubmed: 27909575
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11524-11529
pubmed: 29073081
Acta Neuropathol Commun. 2015 Mar 24;3:14
pubmed: 25853174
Am J Pathol. 2010 Oct;177(4):1977-88
pubmed: 20802182
Neurodegener Dis. 2011;8(4):221-9
pubmed: 21212632
Neurology. 2004 Jun 8;62(11):1977-83
pubmed: 15184600
Mol Neurodegener. 2018 Mar 1;13(1):11
pubmed: 29490706
Nat Neurosci. 2019 Aug;22(8):1217-1222
pubmed: 31235932
Nat Commun. 2020 Nov 30;11(1):6129
pubmed: 33257666
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
J Neuroinflammation. 2018 Sep 21;15(1):274
pubmed: 30241479
J Neurosci. 2013 Feb 27;33(9):3765-79
pubmed: 23447589
Acta Neuropathol. 2021 May;141(5):681-696
pubmed: 33609158
Trends Immunol. 2020 Sep;41(9):771-784
pubmed: 32792173
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
Nat Neurosci. 2019 Jun;22(6):1021-1035
pubmed: 31061494
Neuron. 2007 Feb 1;53(3):337-51
pubmed: 17270732
Brain. 2015 Jun;138(Pt 6):1738-55
pubmed: 25833819
Mol Psychiatry. 2020 Mar 11;:
pubmed: 32161362
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32579671
Alzheimers Dement. 2019 Jul;15(7):888-898
pubmed: 31164314
Nat Commun. 2020 Feb 3;11(1):667
pubmed: 32015339
Brain. 2018 Sep 1;141(9):2740-2754
pubmed: 30052812